WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Bristol-Myers Squibb

Bristol-Myers SquibbBristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

www.bms.com.

Bristol-Myers Squibb RSS Channel

Filters
List of articles in category Bristol-Myers Squibb
Title Published Date
Bristol-Myers Squibb and PsiOxus Therapeutics announce immuno-oncology clinical collaboration 30 June 2016
Ready. Raise. Rise. Campaign 06 May 2016
Bristol-Myers Squibb reports first quarter financial results 28 April 2016
Bristol-Myers Squibb to acquire Padlock Therapeutics, Inc. 23 March 2016
Bristol-Myers Squibb and LabCentral team up in Cambridge, Massachusetts to support promising biotech startup companies 07 March 2016
Bristol-Myers Squibb completes previously announced sale of its HIV R&D portfolio to ViiV Healthcare 22 February 2016
Bristol-Myers Squibb and Dana-Farber Cancer Institute enter into a collaboration agreement 16 February 2016
Bristol-Myers Squibb Foundation awards eight grants totaling nearly $11.5M to make lung and skin cancer screening 01 February 2016
Bristol-Myers Squibb to sell its HIV R&D portfolio to ViiV Healthcare 18 December 2015
Bristol-Myers Squibb and UCLA enter into a collaboration agreement 14 December 2015
Bristol-Myers Squibb Foundation marks World AIDS Day with grants totaling more than $3.5M 01 December 2015
Bristol-Myers Squibb to acquire Cardioxyl Pharmaceuticals, Inc. 02 November 2015
Bristol-Myers Squibb reports third quarter financial results 27 October 2015
Bristol-Myers Squibb's Opdivo (nivolumab) receives expanded FDA approval in previously-treated metastatic non-small cell lung cancer (NSCLC) 12 October 2015
Bristol-Myers Squibb and Moffitt Cancer Center enter into a collaboration agreement 25 September 2015
Bristol-Myers Squibb Employees cycle nearly 2,900 miles to raise money for cancer research 10 September 2015
Bristol-Myers Squibb establishes collaborative Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S. 04 August 2015
Lilly, Bristol-Myers Squibb Restructure Erbitux® (cetuximab) Collaboration in North America 16 April 2015
Bristol-Myers Squibb acquires exclusive license from Novo Nordisk for a discovery research program focused on autoimmune diseases 24 March 2015
FDA approves Opdivo (nivolumab) for the treatment of patients with previously treated metastatic squamous non-small cell lung cancer 05 March 2015
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End

Business & Industry

  • Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
  • CPHI Pharma Awards open to global innovators, scientists, entrepreneurs and social leaders
  • Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
  • BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
  • Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma

Research & Development

  • Candidate found to inhibit malignant melanoma growth
  • A nasal spray protects against coronavirus infection - Effective also against recent immune-evasive variants
  • 'Biohybrid' device could restore function in paralysed limbs
  • Scientists use tardigrade proteins for human health breakthrough
  • DNA treatment could delay paralysis that strikes nearly all patients with ALS
  • Scientists reveal a potential new approach to treating liver cancer
  • Normalizing tumor blood vessels may improve immunotherapy against brain cancer

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA approves first over-the-counter naloxone nasal spray
  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  1. You are here:  
  2. Home
  3. Bristol-Myers Squibb
  4. Bristol-Myers Squibb and Boston Medical Center announce research collaboration to investigate markers of immuno-oncology response and resistance

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.